PuriCore gets clean bill of health

PuriCore, a developer of technology that mimics the body's defensive system, has been cleared by the US Food and Drug Administration (FDA) to market its wound cleaning system as a medical device.

FDA approval is a key milestone for the company - which has its European headquarters in Stafford and is listed on the London stock exchange - allowing it to launch the system commercially in the world's biggest healthcare market.

Effective solution

The company's VASHE system is said to produce an effective solution for wound cleansing and treating acute and chronic skin conditions. According to the global group, it is the first wound cleaning system of its kind that can produce a solution at the point of use by medical staff.

It is based on technology and devices developed by PuriCore that produce hypochlorous acid - a key chemical in the body's natural defences - from the electrolysis of a saline solution.